Oxidative stress in Mexicans with diffuse cutaneous systemic sclerosis

Rheumatology International

Volumn 33, Issue 9, 2013, Pages 2261-2267

  Cruz Dominguez M P ^a,d   Montes Cortes, D H ^b   Olivares Corichi, I M ^c   Vera Lastra, O ^a,d   Medina, G ^a,d   Jara, L J ^a,d  

^a HOSPITAL DE ESPECIALIDADES   (Mexico)

^b Hospital General Centro Medico Nacional La Raza   (Mexico)

^c INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^d UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Acute phase reactants; Diffuse systemic sclerosis; Mexicans; Oxidative stress; Uric acid

Indexed keywords

ANTINUCLEAR ANTIBODY; ANTIOXIDANT; C REACTIVE PROTEIN; CARBONYL DERIVATIVE; CENTROMERE ANTIBODY; DNA TOPOISOMERASE; LIPID; MALONALDEHYDE; SCL 70 ANTIBODY; URIC ACID;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HISPANIC; HUMAN; HYPERURICEMIA; LIPID PEROXIDATION; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; SYSTEMIC SCLEROSIS;

ADULT; BIOLOGICAL MARKERS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; FEMALE; HUMANS; MALE; MIDDLE AGED; OXIDATIVE STRESS; SCLERODERMA, DIFFUSE; URIC ACID;

EID: 84883176445     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-013-2701-8     Document Type: Article

References (48)

1. Haustein UF (2011) Systemic sclerosis - an update. Lab Med 42:562-572
2. Zhou R, Tardivel A, Thorens B, Choi I, Tschopp J (2010) Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol 11:136-140
3. Hu Y, Mao K, Zeng Y, Chen S, Tao Z et al (2010) Tripartite-Motif Protein 30 negatively regulates NLRP3 Inflammasome activation by modulating reactive oxygen species production. J Immunol 185:7699-7705
4. Montuschi P, Barnes PJ, Roberts LJ (2004) Isoprostanes: markers and Mediators of oxidative stress. II FASEB J 18:1791-1800
5. Sfrent-Cornateanu C, Mihai R, Stoian I, Lixandru D, Bara C et al (2008) Antioxidant defense capacity in scleroderma patients. Clin Chem Lab Med 46:836-841
6. Casciola-Rosen L, Wigley F, Rosen A (1997) Scleroderma autoantigens are uniquely fragmented by metal-catalyzed oxidation reactions: implications for pathogenesis. J Exp Med 185:71
7. Servettaz A, Goulvestre C, Kavian N, Nicco C, Guilpain P et al (2009) Selective oxidation of DNA Topoisomerase 1 induces systemic sclerosis in the mouse. J Immunol 182:5855-5864
8. Biondi R, Coaccioli S, Lattanzi S, Puxeddu A, Papini M (2008) Oxidant/antioxidant status in patients with Raynaud's disease. Clin Ter 159:77-81
9. Dooley A, Gao B, Shi-Wen X, Abraham DJ, Black CM et al (2007) Effect of nitric oxide and peroxynitrite on type I collagen synthesis in normal and scleroderma dermal fibroblasts. Free Radic Biol Med 43:253-264
10. Varga J, Abraham D (2007) Systemic sclerosis: a prototypic, multisystem fibrotic disorder. J Clin Investig 117:557-567
11. Seal JB, Gerwetz BL (2005) Vascular dysfunction in ischemia-reperfusion injury. Ann Vasc Surg 19:572-584
12. Sambo P, Baroni SS, Luchetti M, Paroncini P, Dusi S et al (2001) Oxidative stress in scleroderma: maintenance of scleroderma fibroblast phenotype by the constitutive up-regulation of reactive oxygen species generation through the NADPH oxidase complex pathway. Arthr Rheum 44:2653-2664
13. Servettaz A, Guilpain P, Goulvestre C, Chéreau C, Hercend C et al (2007) Radical oxygen species production induced by advanced oxidation protein products predicts clinical evolution and response to treatment in systemic sclerosis. Ann Rheum Dis 66:1202-1209
14. Dimitroulas T, Giannakoulas G, Dimitroula H, Sfetsios T, Parcharidou D et al (2011) Significance of serum uric acid in pulmonary hypertension due to systemic sclerosis: a pilot study. Rheumatol Int 31:263-267
15. Waring WS, Webb DJ, Maxwell RJ (2000) Uric acid as a risk factor for cardiovascular disease. QJM 93:707-713
16. Bos MJ, Koudstaal PJ, Hofman A, Witteman JC, Breteler MM (2006) Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam study. Stroke 37:1503-1507
17. Fang J, Alderman MH (2000) Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA 283:2404-2410
18. Armstrong EJ, Morrow DA, Sabatine MS (2006) Inflammatory biomarkers in acute coronary syndromes: part II: acute-phase reactants and biomarkers of endothelial cell activation. Circulation 113:e152-e155
19. Smyth AE, MacGregor AJ, Mukerjee D, Brough GM, Black CM et al (2003) A cross-sectional comparison of three self-reported functional indices in scleroderma. Rheumatology 42:732-738
20. Yamane K, Ihn H, Asano Y, Yazawa N, Kubo M et al (2000) Clinical and laboratory features of scleroderma patients with pulmonary hypertension. Rheumatology 39:1269-1271
21. Bryan C, Knight C, Black CM, Silman J (1999) Prediction of five-year survival following presentation with scleroderma: development of a simple model using three disease factors at first visit. Arthr Rheum 42:2660-2665
22. Masi AT, Rodanan PG, Medsger TA (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthr Rheum 23:581-590
23. Le Roy EC, Black C, Fleischmajer R, Jablonska S, Krieg T et al (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202-205
24. LeRoy EC, Medsger TAJ (2001) Criteria for the classification of early systemic sclerosis. J Rheumatol 28:1573-1576
25. Furst DE, Clements PJ, Steen VD, Medsger TA Jr, Masi AT et al (1998) The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. J Rheumatol 25:84-88
26. Lau CS, Khan F, Brown R, Belch JJF (1995) Digital blood flow response to body warming, cooling, and Rewarming in patients with Raynaud's phenomenon. Angiology 46:1-10
27. Hunzelmann N, Genth E, Krieg T, Lehmacher W, Melchers I et al (2008) The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement. Rheumatology 47:1185-1192
28. Yagi K (1998) Sample procedure for specific assay of lipid hydroperoxides in serum or plasma. Methods Mol Biol 108:107-110
29. Montes-Cortes DH, Hicks JJ, Ceballos-Reyes G, Garcia-Sanchez JR, Medina-Navarro R et al (2010) Chemical and functional changes of human insulin by in vitro incubation with blood from diabetic patients in oxidative stress. Metabolism 59:935-942
30. Heinecke JW, Li W, Daehnke HL III, Goldstein JA (1993) Dityrosine, a specific marker of oxidation, is synthesized the myeloperoxidase-hydrogen peroxide system of human neutrophils and macrophages. J Biol Chem 268:4069-4077
31. Malencik DA, Sprouse JF, Swanson CA, Anderson SR (1996) Dityrosine: preparation, isolation, and analysis. Anal Biochem 242:202-213
32. Reznick AZ, Packer L (1994) Oxidative damage to proteins: spectrophotometric method for carbonyl assay. Methods Enzymol 233:357-363
33. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275
34. Hicks JJ, Medina-Navarro R (1995) Inhibitory capacity of human serum on induced microsomal lipoperoxidation. Arch Med Res 26:169-172
35. Hicks JJ, Montes-Cortes DH, Cruz-Dominguez MP, Medina-Santillan R, Olivares-Corichi IM (2007) Antioxidants decrease reperfusion induced arrhythmias in myocardial infarction with ST-elevation. Frontiers Biosci 12:2029-2037
36. Pacher Pl, Beckman Js, Liaudet L (2007) Nitric oxide and peroxynitrite in health and disease. Physiol Rev 87:315-424
37. Behrens MI, Silva M, Schmied A, Salech F, Manzur H, Quest AFG et al (2011) Age-dependent increases in apoptosis/necrosis ratios in human lymphocytes exposed to oxidative stress. J Gerontol A Biol Sci Med Sci 66A(7):732-740. doi: 10.1093/gerona/glr039
38. Giulivi C, Davies KJ (1993) Dityrosine and tyrosine oxidation products are endogenous markers for the selective proteolysis of oxidatively modified red blood cell hemoglobin by (the 19 S) proteasome. J Biol Chem 268:8752-8759
39. Rottoli P, Magi B, Cianti R, Bargagli E, Vagaggini C et al (2005) Carbonylated proteins in bronchoalveolar lavage of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis. Proteomics 5:2612-2618
40. Shinkai K, McCalmont TH, Leslie KS (2008) Cryopyrin-associated periodic syndromes and autoinflammation. Clin Exp Dermatol 33:1-9
41. Kang DH, Park SK, Lee IK, Johnson RJ (2005) Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol 16:3553-3562
42. Rossi E, Biasucci LM, Citterio F, Pelliccioni S, Monaco C et al (2002) Risk of myocardial infarction and angina in patients with severe peripheral vascular disease: predictive role of C-reactive protein. Circulation 105:800-803
43. Shoenfeld Y, Gerli R, Doria A, Matsuura E, Cerinic MM et al (2005) Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 112:3337-3347
44. Tsifetaki N, Georgiadis AN, Alamanos Y, Fanis S, Argyropoulou MI (2010) Subclinical atherosclerosis in scleroderma patients. Scand J Rheumatol 39:326-329
45. Bendayan D, Shitrit D, Ygla M, Huerta M, Fink G et al (2003) Hyperuricemia as a prognostic factor in pulmonary arterial hypertension. Respir Med 97:130-133
46. Nagaya N, Uematsu M, Satoh T, Kyotani S, Sakamaki F et al (1999) Serum uric acid levels correlate with the severity and the mortality of primary pulmonary hypertension. Am J Respir Crit Care Med 160:487-492
47. Gilson M, Zerkak D, Wipff J, Dusser D, Dinh-Xuan AT et al (2010) Prognostic factors for lung function in systemic sclerosis: prospective study of 105 cases. Eur Respir J 35(1):112-117
48. Dogan A, Yarlioglues M, Kaya MG, Karadag Z, Dogan S et al (2011) Effect of long-term and high-dose allopurinol therapy on endothelial function in normotensive diabetic patients. Blood Press 20:182-187